Summary
Only the indication-related claim about using VIVITROL as part of a comprehensive management program with psychosocial support is supported by the provided label excerpts. The remaining claims (dose forms, timing relative to opioid discontinuation/withdrawal, receptor effects, side effects, liver injury signs, etc.) are not evaluated because the corresponding FDA label text for those topics was not provided in the prompt, so they are treated as unsupported.
Category Scores
Accurate Statements
Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.
Supported by Section 1 (INDICATIONS AND USAGE): "Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support." Also consistent with Section 14 and Section 17 excerpts provided.
Unsupported Statements
Naltrexone is prescribed to treat alcohol use disorder in certain situations.
The prompt provided only the comprehensive management program psychosocial-support sentence (Section 1) and not the full alcohol use disorder indication language needed to verify wording/conditions for this broader claim.
Naltrexone is prescribed to treat opioid use disorder in certain situations.
The prompt provided only excerpts about psychosocial support; it did not provide the full opioid dependence/indication wording from Section 1 needed to confirm this claim.
In opioid use disorder treatment, naltrexone is used after a person has stopped opioids and is no longer in withdrawal.
No label excerpts regarding opioid discontinuation, withdrawal status, or initiation criteria were provided.
Naltrexone can block opioid effects.
No label excerpts describing receptor blocking or effect on opioid analgesics were provided.
Naltrexone can precipitate withdrawal if opioids are still in the system.
No label excerpts were provided that discuss precipitated withdrawal or opioid presence at initiation.
Prescription naltrexone can be taken as oral naltrexone tablets that are taken daily.
The prompt’s label excerpts relate to VIVITROL (extended-release injectable suspension) and do not provide label text supporting oral tablet dosing claims.
Prescription naltrexone can be given as a monthly extended-release injection.
No label excerpts were provided specifying injection interval (e.g., monthly) for VIVITROL.
A prescriber chooses the formulation based on adherence, preferences, and clinical factors.
No label excerpts were provided discussing how formulation choice is made.
For people being treated for opioid use disorder, opioids must be discontinued before the first dose of naltrexone.
No label excerpts were provided on required opioid discontinuation prior to first dose.
Discontinuing opioids before the first dose of naltrexone is required to avoid precipitated withdrawal.
No label excerpts were provided linking opioid discontinuation to avoidance of precipitated withdrawal.
Discontinuing opioids before the first dose of naltrexone is required to avoid loss of opioid safety.
No label excerpts were provided supporting the concept of avoiding "loss of opioid safety" via opioid discontinuation.
Clinicians assess timing and exposure to determine when it is safe to start naltrexone.
No label excerpts were provided describing clinician assessment of timing/exposure.
Commonly reported side effects of naltrexone include nausea, headache, dizziness, fatigue, and sleep disturbances.
No label excerpts containing adverse reaction frequency/lists were provided.
Some people also experience abdominal discomfort with naltrexone.
No label excerpts containing adverse reaction lists were provided.
Signs of liver injury include unusual fatigue, dark urine, or yellowing of the skin/eyes in the context of naltrexone.
No label excerpts were provided describing hepatotoxicity signs/symptoms.
Naltrexone blocks opioid receptors.
No label excerpts were provided describing mechanism of action or receptor blockade.
While on naltrexone, opioid pain medicines may not work as expected.
No label excerpts were provided describing the effect of naltrexone on opioid analgesics.
Contradictions
Important Omissions
For the non-indication claims (opioid discontinuation/withdrawal timing; precipitation; dosing interval; adverse reactions; liver injury signs; mechanism; effect on opioid analgesia; formulation choice), the prompt does not include the specific FDA label text sections required to verify alignment.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The only evaluated on-label claim supported by provided excerpts is a psychosocial-support requirement. Most other claims were not supported by the provided label text, but the evaluation is limited to alignment with excerpts supplied; no direct contradictions were identified from the provided information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Only the psychosocial-support indication statement is verified by the provided label excerpts; other claims cannot be confirmed due to missing relevant label text in the prompt.
Suggested Improvement
Provide the corresponding FDA label sections (e.g., full INDICATIONS AND USAGE for alcohol/opioid dependence; DOSAGE AND ADMINISTRATION for initiation criteria and injection interval; CONTRAINDICATIONS/WARNINGS for precipitated withdrawal and hepatotoxicity; ADVERSE REACTIONS for side-effect lists; CLINICAL PHARMACOLOGY for mechanism) so each claim can be checked against the exact label wording.